• 1
    Herrero R, Castelselsague X, Pawlita M, Lissowska J, Kee F, Balaram P, Rajkumar T, Sridhar H, Rose B, Pintos J, Fernández L, Idris A, et al. Human papillomavirus and oral cancer: The International Agency for Research on Cancer Multicenter Study. J Natl Cancer Inst 2003; 95: 177283.
  • 2
    Gillison M, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 40720.
  • 3
    Applebaum KM, Furniss CS, Zeka A, Posner MR, Smith JF, Bryan J, Eisen EA, Peters ES, McClean MD, Kelsey KT. Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst 2007; 99: 180110.
  • 4
    Furniss CS, McLean MD, Smith JF, Bryan J, Nelson HH, Peters ES, Posner MR, Clark JR, Eisen EA, Kelsey KT. Human papillomavirus 16 and head and neck squamous cell carcinoma. Int J Cancer 2007; 120: 238692.
  • 5
    Zumbach K, Hoffmann M, Kahn T, Bosch F, Gottschlich S, Görögh T, Rudert H, Pawlita M. Antibodies against oncoproteins E6 and E7 of human papaillomavirus types 16 and 18 in patients with head-and-neck squamous-cell carcinoma. Int J Cancer 2000; 85: 815818.
  • 6
    Zumbach K, Kisseljov F, Sacharova OT, Bosch F, Gottschlich S, Görögh T, Rudert H, Pawlita M. Antibodies against oncoproteins E6 and E7 of human papaillomavirus types 16 and 18 in cervical-carcinoma patients from Russia. Int J Cancer 2000; 85: 31318.
  • 7
    Meschede W, Zumbach K, Braspenning J, Scheffner M, Benitez-Bribiesca L, Luande J, Gissmann L, Pawlita M. Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Micro 1998; 36: 47580.
  • 8
    Smith EM, Ritchie JM, Pawlita M, Rubenstein LM, Haugen TH, Turek LP, Hamsikova E. Human papillomavirus seropositivity and risks of head and neck cancer. Int J Cancer 2007; 120: 82532.
  • 9
    Smith EM, Rubenstein LM, Ritchie JM, Lee JH, Haugen TH, Hamsikova E, Turek LP. Does pretreatment seropositivity to human papillomavirus have prognostic significance for head and neck cancers? Cancer Epidemiol Biomark Prev 2008; 17: 208796.
  • 10
    American Joint Committee on Cancer. AJCC cancer staging manual, 5th edn. Chicago, IL: Lippincott Williams and Wilkins, 1997.
  • 11
    Klussmann JP, Weissenborn SJ, Wieland U, Dries V, Kolligs J, Jungehuelsing M, Eckel HE, Dienes HP, Pfister HJ, Fuchs PG. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 2001; 92: 287584.
  • 12
    Smith EM, Ritchie JR, Summersgill KF, Hoffman HT, Wang DH, Haugen TH, Turek LP. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 2004; 96: 449455.
  • 13
    Chehab FF, Doherty M, Cai SP, Kan YW, Cooper S, Rubin EM. Detection of sickle cell anaemia and thalassaemias [letter]. Nature 1987; 329: 2934.
  • 14
    Ting Y, Manos MM. Detection and typing of genital human papillomaviruses. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds. PCR protocols, a guide to methods and applications. Berkeley, CA: Academic Press, 1990. 356367.
  • 15
    de Roda Husman A-M, Walboomers JMM, van den Brule AJC, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J. Gen. Virol 1995; 76: 105762.
  • 16
    Altschul SF, Madden TL, Schaeffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acid Res 1997; 25: 3389402.
  • 17
    Sehr P, Zumbach K, Pawlita M. A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Meth 2001; 253: 15362.
  • 18
    Hahn GJ, Meeker WQ. Statistical intervals: a guide for practitioners, 1991. New York: Wiley.
  • 19
    Smith EM, Ritchie JM, Summersgill KF, Klussmann JP, Lee JH, Wang D, Haugen TH, Turek LP. Age sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004; 104: 33644.
  • 20
    Smith EM, Wang D, Kim Y, Rubenstein LM, Lee JH, Haugen TH, Turek LP. P16INK4a expression, human papillomavirus, and survival in head and neck cancer. Oral Oncology 2008; 44: 13342.
  • 21
    Smeets SJ, Hesselink AT, Speel E-J, Haesevoets A, Snijders PJ, Pawlita M, Meijer CJ, Braakhuis BJ, Leemans CR, Brakenhoff RH. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007; 121: 246572.
  • 22
    Wiest T, Schwartz E, Enders C, Flechtenmacher C, Bosch FX. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 2002; 21: 151017.
  • 23
    Braakhuis BJ, Snijders PJ, Keune W-J, Meijer CJ, Ruijter-Schippers HJ, Leemans CR, Brakenhoff RH. Genetic patterns in head and neck cancer that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 2004; 96: 9981006.
  • 24
    Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 70920.
  • 25
    Klussmann JP, Gultekin E, Weissenborn SJ, Wieland U, Dries V, Dienes HP, Eckel HE, Pfister HJ, Fuchs PG. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 2003; 162: 74753.